Nurix Therapeutics, Inc. (NRIX)
22.16
-0.19
(-0.85%)
USD |
NASDAQ |
Oct 12, 16:00
22.52
+0.36
(+1.62%)
After-Hours: 20:00
Nurix Therapeutics Net Income (Quarterly) : 549.81M for Aug. 31, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| August 31, 2026 | 549.81M |
| May 31, 2026 | -89.54M |
| February 28, 2026 | -87.17M |
| November 30, 2025 | -78.22M |
| August 31, 2025 | -86.42M |
| May 31, 2025 | -43.46M |
| February 28, 2025 | -56.35M |
| November 30, 2024 | -58.55M |
| August 31, 2024 | -48.96M |
| May 31, 2024 | -44.55M |
| February 29, 2024 | -41.52M |
| November 30, 2023 | -41.96M |
| August 31, 2023 | -36.98M |
| May 31, 2023 | -24.28M |
| February 28, 2023 | -40.73M |
| November 30, 2022 | -46.72M |
| Date | Value |
|---|---|
| August 31, 2022 | -45.71M |
| May 31, 2022 | -45.40M |
| February 28, 2022 | -42.53M |
| November 30, 2021 | -37.70M |
| August 31, 2021 | -28.84M |
| May 31, 2021 | -26.38M |
| February 28, 2021 | -24.28M |
| November 30, 2020 | -19.91M |
| August 31, 2020 | -18.52M |
| May 31, 2020 | 7.58M |
| February 29, 2020 | -12.39M |
| November 30, 2019 | -13.52M |
| August 31, 2019 | -2.427M |
| May 31, 2019 | -3.068M |
| February 28, 2019 | -2.685M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.50B |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 673.06M |
| Total Expenses (Quarterly) | 123.26M |
| EPS Diluted (Quarterly) | 4.73 |
| Enterprise Value | 1.315B |
| Profit Margin (Quarterly) | 81.69% |
| Earnings Yield | 10.42% |
| Operating Earnings Yield | 12.09% |